Flare Therapeutics Presents Part A Data from FX-909 Phase 1 Study at AACR-NCI-EORTC International Conference
Flare Therapeutics Presents Part A Data from FX-909 Phase 1 Study at AACR-NCI-EORTC International Conference GlobeNewswire October 24, 2025 FX-909, the first small molecule targeting PPARG to be tested in humans, showed monotherapy activity in advanced urothelial carcinoma with a favorable safety profile Strong safety, tolerability and efficacy data in a biomarker-defined advanced UC population […]